晚期食管癌的姑息治疗
任鹏， 于振涛 - 中国肿瘤临床, 2013 - cjco.cn
… A phase 2 trial of erlotinib in pa⁃ tients with previously treated squamous cell and …
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced ad⁃ …
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced ad⁃ …
[PDF][PDF] 2018 年胃肠恶性肿瘤研究进展
董秋美， 马冬 - 循证医学, 2019 - jebm.cn
… individual patient data from ASPECCT and WJOG6510G trial which compared Panitumumab
versus Cetuximab in patients with wild⁃type KRAS exon 2 metastatic colorectal cancer[J]. …
versus Cetuximab in patients with wild⁃type KRAS exon 2 metastatic colorectal cancer[J]. …
高敏感格拉斯哥评分对进展期胃癌患者新辅助化疗疗效和预后的预测作用
崔瑶， 李剑， 曹养辉， 刘明月… - Chinese Journal of …, 2017 - search.ebscohost.com
… Phase Ⅱ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced
adenocarcinoma of the oesophagus and gastro⁃ oesophageal junction[J]. Br J Cancer, 2011, …
adenocarcinoma of the oesophagus and gastro⁃ oesophageal junction[J]. Br J Cancer, 2011, …
[PDF][PDF] 小试牛刀: 克唑替尼在ALK 阳性局部晚期非小细胞肺癌新辅助治疗的应用
王志杰， 傅睿 - 循证医学, 2019 - jebm.cn
… individual patient data from ASPECCT and WJOG6510G trial which compared Panitumumab
versus Cetuximab in patients with wild⁃type KRAS exon 2 metastatic colorectal cancer[J]. …
versus Cetuximab in patients with wild⁃type KRAS exon 2 metastatic colorectal cancer[J]. …
[HTML][HTML] 晚期胃癌分子靶向治疗的现状及其发展趋势
曲晶磊， 刘云鹏 - 世界华人消化杂志, 2011 - wjgnet.com
… Currently, chemotherapy is the mainstay of treatment for patients with metastatic gastric …
of patients with advanced gastric cancer, the median survival in all randomized trials remains …
of patients with advanced gastric cancer, the median survival in all randomized trials remains …
[HTML][HTML] 不可切除的局部进展期胃癌术前口服S-1 联合区域动脉灌注化疗栓塞的疗效评价
张玉坤， 郜永顺， 张云飞， 刘琪， 吴刚， 李文才… - 世界华人消化 …, 2015 - wjgnet.com
… METHODS: Clinical data for 183 patients with unresectable locally advanced gastric cancer
who received operation after receiving neoadjuvant chemotherapy from January 2010 to …
who received operation after receiving neoadjuvant chemotherapy from January 2010 to …
晚期结直肠癌多模式维持治疗撷英
朱旭东， 张航瑜， 傅琦涵， 童舟， 刘璐璐， 郑怡… - 肿瘤综合治疗电子 …, 2020 - jmcm2018.com
… treatment models for advanced colorectal cancer. [Key words] … erlotinib after chemotherapy
and bevacizumab in metastatic … of modified FOLFOX6 plus panitumumab in patients with …
and bevacizumab in metastatic … of modified FOLFOX6 plus panitumumab in patients with …
胃癌分子靶向治疗研究新进展
黎军和， 熊建萍 - 中国肿瘤临床, 2015 - cjco.cn
… 一项探讨人源化抗c-Met单克隆抗体onartuzumab联 合FOLFOX6 一线治疗c-Met 阳性,HER-2
阴性… Rilotumumab exposure-re⁃ sponse relationship in patients with advanced or metastatic …
阴性… Rilotumumab exposure-re⁃ sponse relationship in patients with advanced or metastatic …
[HTML][HTML] EGFR 抑制剂在胃癌中的研究进展
涂金花， 余英豪 - 世界华人消化杂志, 2011 - wjgnet.com
… 性与西妥昔单抗(cetuximab)单独及其联合FOLFOX6的治疗晚期胃癌中发现, EGFR基因第1内含
… 剂, 如吉非替尼(gefitinib),埃罗替尼(erlotinib). 这类小分子抑制剂能进入细胞内直接作用于EGFR…
… 剂, 如吉非替尼(gefitinib),埃罗替尼(erlotinib). 这类小分子抑制剂能进入细胞内直接作用于EGFR…
[PDF][PDF] 食管胃结合部腺癌的靶向治疗进展
陈键， 何裕隆 - 消化肿瘤杂志(电子版), 2019 - jdocn.com
… Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced …
in first -line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft …
in first -line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft …